Full-Time

Staff Supplier Engineer

Camera and Cabling

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

San Francisco, CA, USA

In Person

Category
Process Engineering
Required Skills
Six Sigma
SAP Products
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Proven ability to work alongside design engineer and assess supplier capability during the design iteration process
  • Demonstrable knowledge in evaluating and challenging supplier technical, quality, and business capabilities
  • Demonstrable knowledge of a wide range of manufacturing processes including understanding of key input variables for quality, cost and capacity (specialization can be in metal fabrication, plastics, electronics, and/or contract manufacturing)
  • Demonstrable knowledge in manufacturing in a Controlled Environment Room
  • A proven history of implementing Lean/6 Sigma/SPC Programs at suppliers
  • Excellent Project Management skills
  • Excellent written and verbal communication skills including presentations to executive level management
  • Excellent Interpersonal skills and team building skills
  • Excellent analytical and problem solving skills along with good judgment
  • Excellent knowledge of 21 CFR part 820 and ISO 13485 (experience in auditing suppliers to these standards)
  • Significant computer experience using Windows, Word, Excel, Access and ERP Information Systems, preferably SAP
  • Ability to read and interpret detailed mechanical drawings and communicate technical information
  • Experience working with extrusions, braiding, and laser cutting is required
  • BS degree in Engineering or equivalent
  • Minimum 12 years related experience in Supplier Engineering and/or Supplier Development or related field
Responsibilities
  • Select and evaluate suppliers by leading efforts to find new suppliers in an existing or new commodity and works with Engineering to maximize use of the production supply base
  • Create strategies to effectively optimize the supply base by leading efforts to optimize supply networks
  • Drive suppliers to continually improve their business and manufacturing process performance to meet Intuitive’s requirements for supplier excellence including ship to stock programs using a collection of best practices in project management, Six Sigma, Lean, SPC and negotiation by leading these efforts without managerial guidance at several suppliers simultaneously
  • Develop and influence using metrics for supplier part cost, delivery, quality, capacity and capability by creating metrics to measure real improvement and judge required intervention or change at the supplier or in a commodity
  • Drive corrective actions for supplier process by driving suppliers to true root cause analysis and corrective and Preventive actions
  • Drive changes to ISI specifications through influencing and educating resulting in changing specifications and drawings including driving the ECO process to implementation
  • Provide effective and timely supply base health information to management by creating and delivering data-driven supply base information to any level of management at ISI with little or no guidance (including QRB) and provide recommendations
  • Prepare and deliver supplier communications as required by independently working with suppliers on scorecard creation of QBRs, Supplier Summits, etc
  • Ensure DFM by engaging suppliers early in development cycle to feedback manufacturability improvements in the designs prior to production
  • Influence and guide Engineering in choosing suppliers by determining selection criteria for preferred suppliers and leading the team effort to evaluate preferred suppliers
  • Understand the product design requirements and design intent for the sub-assembly or part and determine if the supplier can meet requirements and develop a robust manufacturing process that can scale with volume
  • Work with Design Engineering to develop test methods and acceptance criteria for the supplied part or subassembly
  • Create product supplier landscapes to determine launch readiness and report to management
  • Develop supplier ramp readiness plans by judging business risk based on forecast, supplier capacity, quality performance, and process capability
  • Deliver the following Quality deliverables: pFMEA, Special Process Validations, FAI, and Cpk by leading, training and mentoring suppliers through the pFMEA development, judging process validation requirements and signing-off on protocols as ISI rep, judging process capability with supplier as well as judging FAI suitability
  • Develop the supplier business continuity / disaster recovery plans by managing suppliers to create plans, judge plans for risks and negotiate with suppliers to reduce risks
  • Identify and investigate opportunities for cost reduction and/or quality improvement by judging opportunities and creating strategies to seize those opportunities, completes research and provides data-driven plans to management
  • Review, analyze and close customer complaints, manufacturing variance requests, and first article inspections by judging risk analyses and justifications, determining corrective and preventive actions at suppliers, looks for opportunities with suppliers
Desired Qualifications
  • Experience with GD&T, tolerance stack and CAD experience with 3D modeling tools is a plus

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Simplify Jobs

Simplify's Take

What believers are saying

  • Bariatric surgery market expansion as da Vinci outperforms GLP-1 drugs for sustained weight loss.
  • Ion bronchoscopy system procedures grew 39% YoY with 1,041 installed units capturing lung cancer detection.
  • Less than 5% of eligible surgeries globally performed robotically indicates substantial international adoption runway.

What critics are saying

  • FDA Class II recalls of instruments with fraying cables disrupt 86% of Q1 recurring revenue.
  • FDA safety communication on curved tip staplers halts hospital use, eroding surgeon confidence in reliability.
  • EU MDR recertification deadline December 2028 halts 25% European sales during redesign and testing.

What makes Intuitive Surgical unique

  • 70-80% market share in soft-tissue robotics with 11,395 installed da Vinci systems globally.
  • 85% recurring revenue from instruments, accessories, and service contracts provides predictable cash flow.
  • da Vinci 5 platform expands into cardiac surgery and complex procedures previously requiring open surgery.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Intuitive Surgical who can refer or advise you

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 7th, 2026
Intuitive Surgical emerges as dark horse in anti-obesity market as surgery outperforms GLP-1 drugs

Intuitive Surgical could emerge as a dark horse in the anti-obesity market as bariatric surgery proves more effective than GLP-1 drugs for long-term weight loss. A recent study of over 50,000 patients found surgery patients lost an average of 58 pounds after two years, compared to just 12 pounds for those using GLP-1 medications. The study also showed surgery delivers more sustainable results. Gastric bypass patients maintain around 52% of their excess weight loss after 10 years, whilst GLP-1 users often regain all lost weight after stopping treatment. Intuitive's da Vinci surgical system offers minimally invasive bariatric surgery options. The company generated $10.1 billion in revenue last year, up from $8.4 billion, with profit margins around 28%. Despite shares falling over 20% this year, the company's position in surgical innovation makes it a compelling long-term investment.

Yahoo Finance
Mar 29th, 2026
Intuitive Surgical shares drop 19% YTD, but analysts see 15% upside potential

Intuitive Surgical has experienced recent share price weakness, declining 3% in one day with negative returns over the past week, month and three months. The stock currently trades at $452.66, down 10.1% over one month and 19.45% year-to-date, though three-year total shareholder returns remain strong at 77.19%. The medical technology company reports annual revenue of $10.1 billion and net income of $2.9 billion, maintaining a dominant position in minimally invasive surgical technology. According to one valuation analysis, Intuitive Surgical's fair value sits at $532.46, suggesting the stock is undervalued by approximately 15% at current levels. The analysis projects 12% annual revenue growth over the next five years, supported by recurring revenues from spare parts and software licences, with profit margins expected to reach 30% from the current 28.6%.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical shares up 23% after Jim Cramer's buy recommendation

Intuitive Surgical shares rose 23% following Jim Cramer's recommendation on CNBC's Squawk on the Street in June 2025, where he urged investors to "just go buy ISRG". The medical robotics company experienced a 27% surge in October after reporting third-quarter earnings that beat analyst estimates. Revenue reached $2.51 billion against expectations of $2.40 billion, whilst adjusted earnings per share hit $2.40 versus the predicted $1.98. However, the stock declined 2.7% in January 2026 after Intuitive Surgical released preliminary fourth-quarter results, citing concerns that Medicaid funding cuts and competing products could slow growth of its robotic surgical systems. Despite the recent setback, shares remain up significantly since Cramer's initial endorsement, though they're down 7.8% over the past year.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical faces tariff headwinds and rising competition despite 19% revenue growth to $2.87B

Intuitive Surgical faces headwinds from tariffs and increased competition in the robotic-assisted surgery market, yet its fundamentals remain strong. The medical device company reported fourth-quarter revenue growth of 19% to $2.87 billion, whilst adjusted earnings per share rose 14.5% to $2.53. Procedures using its da Vinci surgical system increased 17%, with the installed base growing 12% to 11,106 units. However, the stock trades at 47.6 times forward earnings, compared to the healthcare sector average of 17.1. New competition is emerging, with Medtronic's Hugo system recently cleared and Johnson & Johnson expected to launch its own device soon. Despite these challenges, Intuitive Surgical maintains advantages through switching costs and extensive real-world data, whilst the underpenetrated robotic-assisted surgery market offers long-term growth potential.

Yahoo Finance
Mar 24th, 2026
ISRG maintains 37% operating margins in Q4 despite 95 bps tariff drag

Intuitive Surgical maintained a 37% operating margin in Q4 despite tariffs creating a 95 basis point drag, alongside higher facility costs and unfavourable product mix from newer platforms like da Vinci 5 and Ion. The company offset these pressures through product cost reductions, component savings and manufacturing efficiencies. Procedure growth of 18% in Q4 and recurring revenue now comprising 81% of total revenues provided operating leverage. Management's 2026 gross margin guidance of 67-68% suggests continued stability, even as tariff headwinds are expected to increase to roughly 1.2% of revenues. Meanwhile, Boston Scientific expanded adjusted operating margins by 100 basis points to 28% in 2025, though tariffs will offset favourable product mix in 2026. The company expects 50-75 basis points operating margin expansion in 2026 through scale efficiencies and supply-chain optimisation.